Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing a significant financing transaction involving its wholly-owned finance subsidiary, American Medical Systems Europe B.V. (AMS Europe). AMS Europe successfully priced and completed the offering of €1.5 billion in senior notes, split between 3.000% Senior Notes due 2031 (€850 million) and 3.250% Senior Notes due 2034 (€650 million). The Company, acting as guarantor, fully and unconditionally guarantees these notes. The net proceeds from this offering, amounting to approximately €1.487 billion after expenses, are earmarked for crucial financial activities. Primarily, the funds will be used to repay AMS Europe's 0.750% Senior Notes due March 8, 2025, along with associated interest. The remaining proceeds will support general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions. This refinancing demonstrates proactive capital management by BSX.
Key Highlights
- 1Boston Scientific's subsidiary, AMS Europe, completed a €1.5 billion senior notes offering.
- 2The offering consists of €850 million in 3.000% Senior Notes due 2031 and €650 million in 3.250% Senior Notes due 2034.
- 3Boston Scientific Corporation provides a full and unconditional guarantee for the issued notes.
- 4Net proceeds of approximately €1.487 billion will be used to repay maturing AMS Europe notes due March 8, 2025.
- 5Remaining proceeds will fund general corporate purposes, including investments, debt reduction, working capital, and potential acquisitions.
- 6The transaction highlights proactive debt management and refinancing by the company.